Amino acid supplement
L-Theanine
L-Theanine after one dose: 50% at ~1.5 h, 25% at 3 h, 12.5% at 4.5 h.
Drawn from the half-life in the app's model, ~1.5 h. The model's figures
- Compound
- L-Theanine
- Symbol
- LTH
- Family
- Supplements
- Parts
- 13
- References
- 15
- Checked
- Last reviewed . Sources are listed below.
Overview
In a description relayed in a 2026 FDA letter, L-theanine, or γ-glutamylethylamide, is a nonprotein amino acid and "the primary free amino acid found in tea".3 Dashwood and Visioli write in Nutrition Research (2025) that it "exhibits structural similarities to the neurotransmitters glutamate and γ-aminobutyric acid (GABA)".4
The most recent pooled analysis in the sources is a systematic review and meta-analysis of 31 randomised controlled trials (n = 1168) by Gerolymos and colleagues (Aix-Marseille University, Molecular Psychiatry, 2026).5 Its authors report that the reduction in acute stress "was modest (SMD = 0.31) and largely influenced by studies with a high risk of bias", and that anxiety effects were "inconsistent and non-significant" apart from one study.5
The app grades the evidence for L-theanine as strong; the sources describe small trials, two of them funded by ingredient or supplement companies, and the grade is not a conclusion drawn from them.2,6 The app's notes describe boosted alpha-wave activity, a 1:2 caffeine to L-theanine pairing for "calm focus", and shorter sleep onset latency at 100 to 400 mg before bed; the sections below set each against what the trials report.
How it works
Sources in this part
Hidese and colleagues write that because its structure resembles L-glutamic acid, "its mechanism of action may be potentially mediated through glutamate receptors", and describe a "partial co-agonistic effect on the N-methyl-D-aspartate receptor".2 In the Scheid kinetics study, L-theanine "seems to be hydrolyzed to ethylamine and glutamic acid", and the authors note that functional effects "may result from L-theanine, ethylamine, or glutamic acid".1
Nobre and colleagues (Unilever, Asia Pacific Journal of Clinical Nutrition, 2008) measured EEG in healthy young participants after 50 mg of L-theanine (n=16) or placebo (n=19) and report "a greater increase in alpha activity across time in the L-theanine condition".7 Kelly and colleagues (Nathan S. Kline Institute, Journal of Nutrition, 2008) gave 100 mg of L-theanine, 50 mg of caffeine, both, or placebo on four testing days and report "lower overall tonic alpha power in the combined treatment" during a cued attention task, a result for the L-theanine and caffeine combination rather than L-theanine alone, whereas Nobre and colleagues measured participants resting with their eyes closed.8,7
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~1.5 h
- Bioavailability
- 99%
- Typical dose
- 100–400 mg/dose
- Route
- Oral
- Time to peak
- ~0.75 h
Sources in this part
The second column of the table holds the app's own figures, shown beside what the sources report.
| Parameter | App's figure | Reported in the sources |
|---|---|---|
| Half-life | ~1.5 h | Hidese and colleagues cite a plasma half-life "reported around 65 min" in humans (about 1.1 h), taken from earlier work and not measured in their trial; the Scheid study sampled blood up to 24 h and its PubMed record gives no half-life2,1 |
| Time to peak | ~0.75 h | Maximum plasma concentration at 0.8 h after 100 mg, 24.3 ± 5.7 μmol/L with capsules and 26.5 ± 5.2 μmol/L with green tea (12 healthy participants, crossover)1 |
| Bioavailability | 99% | None of the sources read gives an absolute oral bioavailability; Scheid and colleagues write that "L-theanine is rapidly absorbed", and plasma AUC rose dose dependently across 50, 100 and 200 mg capsules (3 participants for the 50 and 200 mg doses)1 |
Deeper analysis: Scheid and colleagues, kinetics in healthy participants
In Scheid and colleagues' randomized crossover study (University of Bonn, Journal of Nutrition, 2012), 12 participants took 100 mg of L-theanine as capsules or as green tea, and blood and urine were collected up to 24 h afterwards to measure L-theanine, proteinogenic amino acids and ethylamine.1 The PubMed record carries the publication type "Research Support, Non-U.S. Gov't"; the full text is not in PubMed Central, so its funding statement, author ties and limitations are not reported here.1
Level over 6 weeks
Level, as a share of the peak after one 100 mg dose
As studied: once nightly before sleep (Hidese, 4 weeks)2, twice daily, 400 mg a day in total (Lyon, 6 weeks)9.
An illustration from a pharmacokinetic model using a half-life of 1.5 hours. It is not a measured level or a suggested dose.
Human studies
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Scheid and colleagues, Journal of Nutrition 20121 | Randomized crossover kinetics study | 12 healthy participants; 3 participants on further occasions for 50 and 200 mg | 100 mg as capsules or green tea, single dose; sampling up to 24 h | Plasma peak at 0.8 h (24.3 ± 5.7 μmol/L capsules, 26.5 ± 5.2 μmol/L tea)1 |
| Owen and colleagues, Nutritional Neuroscience 200810 | Randomized controlled trial (PubMed type); 7-day washout | 27 healthy volunteers | 50 mg caffeine with or without 100 mg L-theanine, versus placebo; tests at 60 and 90 min | Combination improved speed and accuracy of attention switching at 60 min; no L-theanine-alone arm10 |
| Haskell and colleagues, Biological Psychology 200811 | Randomised, placebo-controlled, double-blind, balanced crossover | Participants (number not in the PubMed record) | 250 mg L-theanine, 150 mg caffeine, alone and combined; acute | L-theanine alone increased 'headache' ratings and decreased correct serial seven subtractions; the combination improved several speed and accuracy measures11 |
| Hidese and colleagues, Nutrients 20192 | Randomized, placebo-controlled, double-blind crossover; funded by Taiyo Kagaku | 30 healthy adults (9 men, 21 women), mean age 48.3 years | 200 mg/day before sleep for 4 weeks, 2-week washout | PSQI sleep latency, sleep disturbance and sleep medication subscales changed more than with placebo (p = 0.0499, 0.046, 0.047); no between-group difference in any cognitive score; no dropouts2 |
| Moulin and colleagues, Neurology and Therapy 20246 | Randomized, double-blind, placebo-controlled, parallel; funded by Ethical Naturals | 30 healthy adults aged 18–65 with moderate stress, 15 per group | 400 mg/day for 28 days | No significant between-group difference in salivary cortisol; Perceived Stress Scale fell in both groups; 9 adverse events in 6 participants6 |
| Sarris and colleagues, Journal of Psychiatric Research 201912 | Double-blind, randomised, placebo-controlled; 8-week blinded period | 46 participants with DSM-5 generalized anxiety disorder on stable antidepressants | L-theanine 450–900 mg or placebo as an add-on | No difference from placebo on HAMA (p = 0.73) or Insomnia Severity Index (p = 0.35); greater sleep satisfaction (ISI item 4, p = 0.015)12 |
| Lyon and colleagues, Alternative Medicine Review 20119 | Randomized, double-blind, placebo-controlled | 98 boys aged 8–12 with ADHD | 400 mg/day as four 100 mg chewable tablets for 6 weeks | Higher actigraphy sleep percentage and sleep efficiency; sleep latency and other parameters unchanged9 |
| Gerolymos and colleagues, Molecular Psychiatry 20265 | Systematic review and meta-analysis | 31 randomised controlled trials, n = 1168, healthy and clinical populations | Single 200 mg dose 30–60 min before testing; one study 400 mg/day for 8 weeks | Choice reaction time SMD 0.51 (95% CI 0.25-0.77); acute stress SMD 0.31, driven by high-risk-of-bias studies; no serious adverse events reported5 |
Deeper analysis: Hidese and colleagues, 2019
Hidese and colleagues reported a randomized, placebo-controlled, double-blind crossover trial in Nutrients in 2019, in 30 adults (nine men and 21 women, mean age 48.3 years) with no major psychiatric illness.2 Participants took 200 mg/day of Suntheanine or matching placebo tablets before sleep each night for four weeks, with a two-week wash-out between periods, and "the compliance was checked only verbally".2 Depression (SDS), trait anxiety (STAI) and sleep (PSQI) scales were primary measures, with Trail-Making, Stroop and BACS tests for cognition.2 Against placebo, the changes in the SDS and total PSQI showed "a non-statistically significant trend" (p = 0.084 and 0.073), and only the PSQI sleep latency, sleep disturbance and sleep medication subscales were significantly greater (p = 0.0499, 0.046 and 0.047).2 For cognition, BACS verbal fluency and executive function rose within the L-theanine period (p = 0.001 and 0.031), Trail Making Test A and B improved within the placebo period, and score changes between L-theanine and placebo did not differ significantly for any cognitive function; in the lower-scoring half (n = 15) verbal fluency improved more with L-theanine (p = 0.002).2 The authors report no dropouts and that "adverse events were not apparent during the intervention period", and that four weeks of L-theanine "had no significant effect on cortisol or immunoglobulin A levels in the saliva or serum".2 Their stated limitations include that possible biases such as tea consumption, medicine intake and diet "were not accounted for", that only about 20% of measures differed against placebo, "suggesting that the effects are not large on daily function of the participants", and that the sample "may have been insufficient, which is subject to type II errors".2 The study was supported by funding from Taiyo Kagaku Co., Ltd., and two authors (Yasukawa and Ozeki) are employees of that company, which supplied the L-theanine and placebo tablets.2
Deeper analysis: Moulin and colleagues, 2024
Moulin and colleagues (KGK Science, Neurology and Therapy, 2024) randomized 30 healthy adults aged 18 to 65 with moderate stress, 15 per group, to a branded L-theanine at 400 mg/day or placebo for 28 days.6 A total of 48 people were screened, 30 were enrolled, and "all participants completed the study".6 The primary outcome, change in salivary cortisol at Days 14 and 28, showed no separation: "There were no significant differences between groups for change in salivary cortisol", and the authors add that "a placebo effect was observed".6 Perceived Stress Scale scores fell by 12.92% (p = 0.051) and 17.98% (p = 0.04) at Days 14 and 28 on L-theanine, and by 9.74% (p = 0.061) and 17.88% (p = 0.009) on placebo, with no significant difference between groups.6 On the Depression, Anxiety and Stress Scale-21, the total score at Day 28 fell more in the placebo group than in the L-theanine group (p = 0.017), as did the stress subscale (p = 0.012), a result the authors describe as "the worsening in DASS-21" for those on L-theanine.6 Stroop correct reaction time improved on L-theanine and, at Day 28, on placebo (p = 0.005), with "no significant between-group differences in RT outcomes".6 On actigraphy the L-theanine group showed "significantly reduced light sleep after 14 and 28 days compared to placebo (p ≤ 0.040)", while "there were no significant between-group differences in subjective sleep data reported from the HPSQI".6 Nine adverse events were reported by six participants (eight events in five on L-theanine, one on placebo); two, metallic taste and dry mouth, were "classified as mild and possibly related", and all resolved by the end of the study or at follow-up.6 The authors name as limitations that the population "was comprised primarily of females", which may limit generalizability, and the inter-individual variability that larger trials could reduce; they also suggest the timing of cortisol collection "might have missed the best timing" and note that mean morning salivary cortisol was significantly higher at baseline in the placebo group.6 The research was "funded by Ethical Naturals, Inc.", one author (Xiong) is an employee of Ethical Naturals and four are employees of KGK Science Inc.6 The ClinicalTrials.gov entry NCT05808595 lists the trial as Phase 2 and completed, with Ethical Naturals, Inc. as lead sponsor and KGK Science Inc. as a collaborator.13
Deeper analysis: Sarris and colleagues, 2019
Sarris and colleagues (Western Sydney University and the University of Melbourne, Journal of Psychiatric Research, 2019) ran a 10-week study, with an 8-week double-blind placebo-controlled period, in 46 participants with a DSM-5 diagnosis of generalized anxiety disorder.12 L-theanine "did not outperform placebo for anxiety reduction on the HAMA (p = 0.73) nor insomnia severity on the Insomnia Severity Index (ISI; p = 0.35)".12 Secondary signals were greater self-reported sleep satisfaction (ISI item 4; p = 0.015) and a separation on the ISI among those with non-clinical insomnia symptoms (ISI ≤ 14; p = 0.007), while "no significant cognitive effects" were revealed.12 The authors call it a "preliminary study" that "did not support the efficacy of L-theanine in the treatment of anxiety symptoms in GAD".12 The PubMed record lists "Research Support, Non-U.S. Gov't" and gives no funding statement, adverse event counts or detailed limitations; the full text is not in PubMed Central and was not read.12
Deeper analysis: Lyon and colleagues, 2011
Lyon and colleagues (Alternative Medicine Review, 2011) randomized 98 boys aged 8 to 12 with physician-confirmed ADHD, stratified by stimulant medication use, to L-theanine or an identical-tasting chewable placebo for six weeks.9 Boys on L-theanine had "significantly higher sleep percentage and sleep efficiency scores", a "non-significant trend" for less time awake after sleep onset, and unchanged sleep latency; parent questionnaire data did not correlate significantly with actigraphy.9 The authors write that L-theanine "at relatively high doses was well tolerated with no significant adverse events", and call for "larger, long-term studies".9 The PubMed record names the product as Suntheanine from Taiyo Kagaku and lists three authors, one affiliated with the University of British Columbia; it gives no funding statement or author disclosure.9
Deeper analysis: the caffeine pairing trials (Owen, Haskell, Kelly)
Owen and colleagues (Unilever, Nutritional Neuroscience, 2008) tested 50 mg of caffeine with and without 100 mg of L-theanine against placebo in 27 healthy volunteers.10 They report that caffeine improved subjective alertness at 60 min and attention-switching accuracy at 90 min, and the combination improved speed and accuracy of attention switching at 60 min and reduced susceptibility to distracting information in the memory task at 60 and 90 min.10 Haskell and colleagues (Northumbria University, Biological Psychology, 2008) used 250 mg of L-theanine and 150 mg of caffeine, alone and combined, in a balanced crossover study; L-theanine alone "increased 'headache' ratings and decreased correct serial seven subtractions".11 The app's 1:2 caffeine to L-theanine pairing matches the Owen and Kelly doses (50 mg and 100 mg) but not Haskell's 150 mg and 250 mg.10,8,11 The PubMed records for Owen, Haskell and Kelly carry no funding statements, participant numbers (Haskell, Kelly) or authors' limitations, and the full texts are not in PubMed Central and were not read.
Deeper analysis: Gerolymos and colleagues, 2026
Gerolymos and colleagues (Molecular Psychiatry, 2026) pooled 31 randomised trials (n = 1168) of oral L-theanine against placebo; the primary outcome was "the acute effect of a single dose on stress in healthy adults".5 For that outcome the reduction was "modest (SMD = 0.31) and largely influenced by studies with a high risk of bias", and "no significant effect on fatigue was observed".5 The authors call for confirmation of a possible antidepressant effect "in high-quality trials, especially in clinical populations", and "no serious adverse events were reported".5 The competing-interest statement says that "Dr Guillaume Fond founded a company selling dietary supplements"; the PubMed record lists the publication type "Research Support, Non-U.S. Gov't" and does not give the authors' own limitations section.5
Doses reported in studies and on labels
| Source | Dose and route | Schedule and length | People and comparator |
|---|---|---|---|
| Scheid 20121 | 50, 100 and 200 mg capsules; 100 mg in green tea; oral | Single dose; sampling to 24 h | Healthy participants; 12 on 100 mg, 3 on 50 and 200 mg; capsule against tea crossover |
| Owen 200810 | 100 mg L-theanine with 50 mg caffeine | Single doses 7 days apart; tests at 60 and 90 min | 27 healthy volunteers; against 50 mg caffeine alone and placebo |
| Hidese 20192 | 200 mg/day tablets; oral | Before sleep nightly for 4 weeks | 30 healthy adults; crossover against placebo with 2-week washout |
| Moulin 20246 | 400 mg/day; oral | 28 days | 30 adults with moderate stress; 15 per group against placebo |
| Lyon 20119 | 400 mg/day as four 100 mg chewable tablets, two twice daily; oral | 6 weeks | 98 boys aged 8 to 12 with ADHD; against identical-tasting placebo |
| Sarris 201912 | 450–900 mg, as an add-on to antidepressants; oral | 8-week double-blind period | 46 participants with generalized anxiety disorder; against matching placebo |
| Gerolymos 20265 | Single 200 mg dose 30–60 min before testing; one study 400 mg/day | Single dose; one study 8 weeks | Pooled randomised trials against placebo |
| FDA letter on GRN 001311 (2026)3 | Notifier's estimate for a food ingredient, not a supplement dose | 1,242 mg/person/day at the 90th percentile of eaters in the US population aged 2 years and older | Notifier's summary of trials: up to 900 mg/day for up to 12 weeks |
The app's typical dose of 100 to 400 mg per dose sits inside the range of the trials above, which span 50 to 900 mg.1,12 A DailyMed search for L-theanine returned one label, a 2011 multi-ingredient homeopathic spray, which is not used here, and no single-ingredient L-theanine drug label was identified.
Side effects reported
In the Hidese trial, the authors report no dropouts and that "adverse events were not apparent during the intervention period" over four weeks at 200 mg/day.2 In the Moulin trial at 400 mg/day for 28 days, nine adverse events occurred in six participants (eight in five on L-theanine, one on placebo), and the two judged possibly related, metallic taste and dry mouth, were classified as mild.6 Lyon and colleagues report "no significant adverse events" at 400 mg daily in boys with ADHD, and Gerolymos and colleagues report that no serious adverse events were reported across the pooled trials.9,5 The FDA letter relays a notifier's summary of human trials at up to 900 mg/day for up to 12 weeks "with no serious adverse events reported", and a pivotal 13-week dietary toxicity study with "no treatment-related adverse effects at the highest dose tested, 4,000" mg/kg body weight/day, which is animal toxicity data; the letter does not name the species for that study.3 Türközü and Şanlier write that acute and chronic toxicity tests "express that L-theanine is reliable in general even if it is consumed too much with diet", while also stating that it "has not revealed a clear evidence-based result yet regarding theanine metabolism, health effects, and its safety".14
Bloodwork and markers
Sources in this part
The app lists no health markers to monitor for L-theanine. In the Hidese trial, body mass index and biochemical data showed "no significant alteration" after four weeks at 200 mg/day, and salivary and serum cortisol and immunoglobulin A were not significantly affected.2 In the Moulin trial, out-of-range laboratory values were "deemed not clinically relevant" and there were "no clinically relevant changes in vital signs".6
Regulatory and anti-doping status
Sources in this part
FDA has issued "no questions" letters on four notices about L-theanine as a food ingredient: GRN 000209 (letter dated February 5, 2007), GRN 000338 (L-theanine extracted from tea leaves, November 5, 2010), GRN 000501 (chemically synthesized, July 30, 2014) and GRN 001311 (L-theanine produced by Escherichia coli CICC 11189s, signed September 4, 2026).3 The 2026 letter states that it "is not an affirmation that L-theanine is GRAS under 21 CFR 170.35", so these letters are not drug approvals.3 No FDA drug approval for L-theanine was identified in the DailyMed search above. L-theanine is not named in the text of the World Anti-Doping Agency's 2026 Prohibited List that was read.15 The same list states that caffeine is "included in the 2026 Monitoring Program and are not considered Prohibited Substances".15
What is not known
Sources in this part
None of the sources read gives an absolute oral bioavailability for L-theanine, so the app's 99% has no figure from the sources beside it.1 The half-life in people rests on a figure cited as "around 65 min" in one trial paper, against the app's 1.5 h; the kinetics study's PubMed record reports no half-life.2,1 The single-compound studies above enrolled 12 to 98 participants (Hidese and colleagues call their n = 30 sample "a small population"), use different doses from 50 to 900 mg, and in two of them the product's supplier funded the work and employs authors.2,6,1 The app's note that L-theanine reduces sleep onset latency at 100 to 400 mg is only partly matched: Lyon and colleagues report unchanged sleep latency at 400 mg/day, while Hidese and colleagues report a greater change in the PSQI sleep latency subscale than with placebo at 200 mg/day (p = 0.0499).9,2
Frequently asked questions
What is the half-life of L-theanine?
How long does L-theanine take to reach its peak level?
The Scheid study found a maximum plasma concentration 0.8 hours after 100 mg, and the app lists about 0.75 hours.1
What is the bioavailability of L-theanine?
The app lists 99%, and none of the sources read gives an absolute bioavailability figure for comparison.1
Is L-theanine banned by WADA?
Is L-theanine FDA approved?
FDA has issued "no questions" letters on GRAS notices for L-theanine as a food ingredient, most recently for GRN 001311 in September 2026, and these are not drug approvals.3 No single-ingredient L-theanine drug label was identified in a DailyMed search.
Did randomized trials find that L-theanine reduces anxiety?
What did trials report about L-theanine and sleep?
In the Hidese crossover at 200 mg/day for four weeks, the PSQI sleep latency, sleep disturbance and sleep medication subscales changed significantly more than with placebo (p = 0.0499, 0.046 and 0.047).2 In boys with ADHD at 400 mg/day for six weeks, actigraphy sleep percentage and sleep efficiency were higher while sleep latency was unchanged.9 In 46 adults with generalized anxiety disorder on stable antidepressants, adjunctive L-theanine at 450 to 900 mg did not outperform placebo on the Insomnia Severity Index (p = 0.35), while self-reported sleep satisfaction (ISI item 4) was greater (p = 0.015).12
What side effects were reported in L-theanine trials?
Moulin and colleagues reported nine adverse events in six participants over 28 days at 400 mg/day, eight of them in five people on L-theanine.6 Metallic taste and dry mouth were classified as mild and possibly related to the product.6 Hidese and colleagues report that adverse events were not apparent during the intervention period.2
What happened when L-theanine was combined with caffeine in trials?
In Owen and colleagues' 27-person study, 100 mg of L-theanine with 50 mg of caffeine improved speed and accuracy of attention switching at 60 minutes, and no arm gave L-theanine alone.10 In Kelly and colleagues' study, no effects were detected for 100 mg of L-theanine alone, while the combination with 50 mg of caffeine raised hit rate and d' against placebo.8
Guides, tools and comparisons
References
- Scheid L, et al. Kinetics of L-theanine uptake and metabolism in healthy participants are comparable after ingestion of L-theanine via capsules and green tea. J Nutr 2012. PMID 23096008
- Hidese S, et al. Effects of L-Theanine Administration on Stress-Related Symptoms and Cognitive Functions in Healthy Adults: A Randomized Controlled Trial. Nutrients 2019. PMID 31623400
- U.S. Food and Drug Administration. Response letter, GRAS Notice No. GRN 001311, L-theanine produced by Escherichia coli CICC 11189s, 4 September 2026. FDA GRAS letter
- Dashwood R, Visioli F. l-theanine: From tea leaf to trending supplement - does the science match the hype for brain health and relaxation? Nutr Res 2025. PMID 39854799
- Gerolymos C, Saddier E, Boyer L, Fond G. Cognitive and affective effects of L-Theanine: a systematic review and meta-analysis of 31 randomized trials. Mol Psychiatry 2026. PMID 42410082
- Moulin M, et al. Safety and Efficacy of AlphaWave L-Theanine Supplementation for 28 Days in Healthy Adults with Moderate Stress: A Randomized, Double-Blind, Placebo-Controlled Trial. Neurol Ther 2024. PMID 38758503
- Nobre AC, Rao A, Owen GN. L-theanine, a natural constituent in tea, and its effect on mental state. Asia Pac J Clin Nutr 2008. PMID 18296328
- Kelly SP, Gomez-Ramirez M, Montesi JL, Foxe JJ. L-theanine and caffeine in combination affect human cognition as evidenced by oscillatory alpha-band activity and attention task performance. J Nutr 2008. PMID 18641209
- Lyon MR, Kapoor MP, Juneja LR. The effects of L-theanine (Suntheanine) on objective sleep quality in boys with attention deficit hyperactivity disorder (ADHD): a randomized, double-blind, placebo-controlled clinical trial. Altern Med Rev 2011. PMID 22214254
- Owen GN, Parnell H, De Bruin EA, Rycroft JA. The combined effects of L-theanine and caffeine on cognitive performance and mood. Nutr Neurosci 2008. PMID 18681988
- Haskell CF, Kennedy DO, Milne AL, Wesnes KA, Scholey AB. The effects of L-theanine, caffeine and their combination on cognition and mood. Biol Psychol 2008. PMID 18006208
- Sarris J, et al. L-theanine in the adjunctive treatment of generalized anxiety disorder: A double-blind, randomised, placebo-controlled trial. J Psychiatr Res 2019. PMID 30580081
- Ethical Naturals, Inc. The Safety and Efficacy of AlphaWave L-Theanine on Adults Who Experience Moderate Stress on a Regular Basis. ClinicalTrials.gov NCT05808595. NCT05808595
- Türközü D, Şanlier N. L-theanine, unique amino acid of tea, and its metabolism, health effects, and safety. Crit Rev Food Sci Nutr 2017. PMID 26192072
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list